drugset
drugset / Trial / NCT05310253

Stress & Social Cognition in BPD (part 2)

NCT05310253 ↗

Completed 240 enrolled Charite University, Berlin, Germany
NaFactorialTriple-blindOther

Summary

The investigators will examine how a combination of pharmacological mineralocorticoid receptor (MR) stimulation and psychosocial stress will influence prosocial behavior in patients with Borderline Personality Disorder (BPD) compared to healthy controls (HC).

Timeline

Start
2022-02-01
Primary completion
2025-03-01
Completion
2025-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludrocortisone Other / unclassified 0.4 mg Oral

Indications

borderline personality disorder